0GZK.LSE Ion Beam Applications S.A.
- Market cap
- EUR 496M
- P/E
- 131.6x
- P/B
- -
- ROE
- -
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0GZK.LSE undervalued?
Graham numberThe Graham number of Ion Beam Applications S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ion Beam Applications S.A. fundamental analysis
No fundamental analysis for Ion Beam Applications S.A. yet.
Ion Beam Applications S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ion Beam Applications S.A.
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation …
Full company profileIon Beam Applications S.A. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ion Beam Applications S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2023 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 329M | 236M | 257M | - |
| Gross Profit | 139M | 67.4M | 94.2M | - |
| Operating Income | 29.2M | -20.8M | 3.35M | - |
| Net Income | 24.4M | -39.2M | -4.40M | - |
| Balance Sheet | ||||
| Total Assets | 381M | 333M | 392M | - |
| Total Liabilities | 230M | 224M | 289M | - |
| Shareholders' Equity | 150M | 109M | 103M | - |
| Cash & Short-term Investments | 74.6M | 27.3M | 36.4M | - |
| Total Debt | 27.8M | 19.3M | 43.3M | - |
| Cash Flow | ||||
| Operating Cash Flow | -17.0M | -44.6M | -18.5M | - |
| Capital Expenditure | 13.0M | 15.3M | 18.7M | - |
| Ratios | ||||
| ROE | 16.3% | -36.1% | -4.3% | - |
| ROA | 6.4% | -11.8% | -1.1% | - |
| Net Profit Margin | 7.4% | -16.6% | -1.7% | - |
| Debt to Equity | 0.18x | 0.18x | 0.42x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ion Beam Applications S.A. dividends
Ion Beam Applications S.A. has not paid dividends in the last 8 fiscal years.
Who owns Ion Beam Applications S.A.
- Insiders 36.61%
- Institutions 21.20%
- Public & others 42.19%
- Shares outstanding 29.3M
- Free float 26.2M
Ion Beam Applications S.A. company profile
- Company name
- Ion Beam Applications S.A.
- Ticker
- 0GZK.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 2,264
- Fiscal year end
- December
- Address
- 3, Chemin du Cyclotron, Louvain-la-Neuve, Belgium, 1348
- Phone
- 32 1 047 58 11
- Website
- iba-worldwide.com
About Ion Beam Applications S.A.
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Ion Beam Applications S.A. management
8- Mr. Olivier LegrainCEO, MD & Vice Chairman · born 1968
- Mr. Yves JongenFounder, Chief Research Officer & Executive Director · born 1947
- Ms. Catherine VandenborreCFO, Chief Ventures & Corporate Officer · born 1971
- Mr. Henri de RomreeDeputy CEO, Internal Director & Managing Director · born 1976
- Mr. Thomas PevenageHead of Corporate Finance & Investments
- Olivier LechienCorporate Communication Director
- Thomas CanonSustainability Program Director
- Bruno ScutnairePresident of IBA RadioPharma Solutions